US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,960.11

+23.240.79%

Number of Gainers:1

Number of Losers:4

Number of Flat:- -

PE:- -

High:2,977.08

Open:2,936.83

Low:2,923.29

Close:2,936.86

Volume:9.04M

Turnover:256.25M

Market Cap:49.39B

Float Cap:46.11B

Loading ...

Mayne Pharma Group Resolves US Patent Litigation With Teva Pharmaceuticals; Shares Gain 3%

MT Newswires Live

Evofem Biosciences Amends Debt Maturity Terms with Adjuvant

Teva price target raised to $47 from $42 at Barclays

Teva : Barclays Raises Target Price to $47 from $42

THOMSON REUTERS

MannKind CEO to Join Chronic Respiratory Disease Panel at Chardan Healthcare Conference

Femasys doubles enrolling sites in FemBloc FINALE Pivotal Trial

Femasys Doubles Enrolling Sites to 12 in FemBloc Finale Pivotal Trial for Permanent Birth Control

Oppenheimer Upbeat on Veru, Says 'come for the Lean Mass, Stay for the Muscle Function'

Press Release: Daré Bioscience Launches "CEO Corner" Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities

Teva : Oppenheimer Raises Target Price to $52 from $50

THOMSON REUTERS

MannKind Says HFSA Analyses Show Furoscix ReadyFlow Autoinjector Matches IV Furosemide Urine Output

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says

MT Newswires Live

Teva Pharmaceutical on Track for Highest Close Since February 2017

Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says

MT Newswires Live

Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults

MT Newswires Live

Teva announces FDA approval for Weltruza

Dare Bioscience to present Sildenafil Cream data at SMSNA meeting

Daré Bioscience Reports Phase 1 Data Showing 187-Fold Lower Peak Plasma Sildenafil with 3.6% Topical Cream vs Oral Dose

Femasys to Exhibit at ASRM Scientific Congress & Expo

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2960.1067,"timestamp":1792180799999,"preClose":2936.8623,"halted":0,"volume":9035156,"delay":0,"changeRate":0.007915,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":23.244385,"latestTime":"10-16 16:00:00 EDT","open":2936.8315,"high":2977.083,"low":2923.29,"amount":256245845.102161,"amplitude":0.018316,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.364107,"peRate":78.457203,"turnoverRate":0.006292,"increases":1,"decrements":4,"flats":0,"marketCap":49392266636,"floatMarketCap":46111365470},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2977.083,"amplitude":0.018316,"preClose":2936.8623,"low":2923.29,"pbRate":"6.364107","latestPrice":2960.1067,"volume":9035156,"delay":0,"open":2936.8315,"prevYearClose":2379.9924,"prevWeekClose":2937.559,"prevMonthClose":2843.1685,"prevQuarterClose":2843.1685,"fiveDayClose":2937.559,"twentyDayClose":2796.6025,"sixtyDayClose":2355.7476,"secType":"PLATE","market":"US","turnoverRate":0.006292,"peRate":78.457203,"marketCap":49392266636,"floatMarketCap":46111365470,"timestamp":1792180799999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":1,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2675566715","title":"Mayne Pharma Group Resolves US Patent Litigation With Teva Pharmaceuticals; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675566715","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675566715?lang=en_us&edition=fundamental","pubTime":"2026-10-16 07:43","pubTimestamp":1792107806,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  reached a settlement with Teva Pharmaceuticals USA to resolve litigation related to Imvexxy and the associated US Food and Drug Administration Orange Book-listed patents, according to a Friday filing with the Australian bourse.The US Paragraph IV litigation was brought by Mayne Pharma and TherapeuticsMD.The settlement provides a pathway for the potential entry of a Teva Pharmaceuticals generic product on Sept. 2, 2032, or earlier under certain circumstances, subject to court approval. It does not include any financial payment between the parties.Imvexxy is a vaginal insert used in the treatment of moderate to severe dyspareunia, or pain associated with sexual intercourse, due to menopause.Mayne Pharma shares gained 3% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4557","BK4566","BK7096","BK4559","BK4584","MYX.AU","BK4585","BK4596","BK4588","LU1983299246.USD","BK4007","LU2324357040.USD","BK7508","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675537430","title":"Evofem Biosciences Amends Debt Maturity Terms with Adjuvant","url":"https://stock-news.laohu8.com/highlight/detail?id=2675537430","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675537430?lang=en_us&edition=fundamental","pubTime":"2026-10-16 04:09","pubTimestamp":1792094947,"startTime":"0","endTime":"0","summary":"Evofem Biosciences amends debt maturity terms with AdjuvantEvofem Biosciences amended its Adjuvant convertible promissory notes agreement on October 9, 2026, setting maturity at December 1, 2026.Earli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nNDL55jS1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675583557","title":"Teva price target raised to $47 from $42 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2675583557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675583557?lang=en_us&edition=fundamental","pubTime":"2026-10-15 17:50","pubTimestamp":1792057829,"startTime":"0","endTime":"0","summary":"Barclays analyst Glen Santangelo raised the firm’s price target on Teva (TEVA) to $47 from $42 and keeps an Overweight rating on the shares as part...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-47-from-42-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-47-from-42-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","BK4584","LU1983299246.USD","BK4596","LU2324357040.USD","TEVA","BK4588","BK4559","BK4585","BK4566","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675930035","title":"Teva : Barclays Raises Target Price to $47 from $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2675930035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675930035?lang=en_us&edition=fundamental","pubTime":"2026-10-15 17:14","pubTimestamp":1792055675,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nFWN4610U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1983299246.USD","BK4007","BK4584","BK4559","BK4585","TEVA","BK4588","BK4596","BK4566","LU2324357040.USD","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675380322","title":"MannKind CEO to Join Chronic Respiratory Disease Panel at Chardan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2675380322","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675380322?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:03","pubTimestamp":1792008198,"startTime":"0","endTime":"0","summary":"MannKind CEO to Join Chronic Respiratory Disease Panel at Chardan Healthcare ConferenceMannKind will participate in the Chardan Healthcare Conference on Oct. 20, 2026.CEO Michael Castagna will join a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nNDL9Gcjph:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BQXX3C00.GBP","BK4139","IE00BN0W2W23.USD","RCKT","MNKD","BK4112","BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4584","BK4588","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675834750","title":"Femasys doubles enrolling sites in FemBloc FINALE Pivotal Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2675834750","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675834750?lang=en_us&edition=fundamental","pubTime":"2026-10-14 21:16","pubTimestamp":1791983791,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-doubles-enrolling-sites-in-fembloc-finale-pivotal-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-doubles-enrolling-sites-in-fembloc-finale-pivotal-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4539","FEMY","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675342180","title":"Femasys Doubles Enrolling Sites to 12 in FemBloc Finale Pivotal Trial for Permanent Birth Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2675342180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675342180?lang=en_us&edition=fundamental","pubTime":"2026-10-14 21:00","pubTimestamp":1791982848,"startTime":"0","endTime":"0","summary":"Femasys doubles enrolling sites to 12 in FemBloc FINALE pivotal trial for permanent birth controlFemasys doubled actively enrolling U.S. sites to 12 for its FemBloc FINALE pivotal trial in non-surgica","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nNDLcf53WS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BQXX3F31.USD","FEMY","SG9999014005.SGD","SG9999014021.USD","NDAQ","BK4584","IE00B64PRP62.GBP","BK4588","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4082","IE00BQXX3C00.GBP","BK4539","BK4585","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","BCDF","LU2095319765.USD","BK4112","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675534928","title":"Oppenheimer Upbeat on Veru, Says 'come for the Lean Mass, Stay for the Muscle Function'","url":"https://stock-news.laohu8.com/highlight/detail?id=2675534928","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675534928?lang=en_us&edition=fundamental","pubTime":"2026-10-14 19:53","pubTimestamp":1791978825,"startTime":"0","endTime":"0","summary":"BUZZ-Oppenheimer upbeat on Veru, says 'come for the lean mass, stay for the muscle function'** Brokerage Oppenheimerratesdrug developer Veru's stockVERU.O\"outperform\" with a PT of $24as it sees consid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nL4N46012N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4557","VERU","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675535783","title":"Press Release: Daré Bioscience Launches \"CEO Corner\" Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2675535783","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675535783?lang=en_us&edition=fundamental","pubTime":"2026-10-13 21:15","pubTimestamp":1791897300,"startTime":"0","endTime":"0","summary":"New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4555","BKWO","TM","DARE","03160","BK4604","NVIB","BK4588","BK4584","BK4099","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674282183","title":"Teva : Oppenheimer Raises Target Price to $52 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2674282183","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674282183?lang=en_us&edition=fundamental","pubTime":"2026-10-12 14:07","pubTimestamp":1791785241,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nFWN45Y1CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4596","LU2324357040.USD","LU1983299246.USD","BK4584","BK4585","BK4557","BK4007","BK4566","BK4559","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674674608","title":"MannKind Says HFSA Analyses Show Furoscix ReadyFlow Autoinjector Matches IV Furosemide Urine Output","url":"https://stock-news.laohu8.com/highlight/detail?id=2674674608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674674608?lang=en_us&edition=fundamental","pubTime":"2026-10-10 08:00","pubTimestamp":1791590423,"startTime":"0","endTime":"0","summary":"MannKind says HFSA analyses show Furoscix ReadyFlow autoinjector matches IV furosemide urine outputMannKind flagged new clinical analyses on Furoscix ReadyFlow, with results presented at HFSA 2026 on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261010:nNDL6fRFC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","BK4584","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","MNKD","BK4588","LU2210150020.SGD","SG9999014005.SGD","BCDF","BK4585","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00BQXX3D17.EUR","BK4139","NDAQ","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674867476","title":"MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674867476","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674867476?lang=en_us&edition=fundamental","pubTime":"2026-10-10 08:00","pubTimestamp":1791590400,"startTime":"0","endTime":"0","summary":"Furoscix ReadyFlow   Furoscix ReadyFlow   Furoscix ReadyFlow   Furoscix ReadyFlow  New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine outp","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/10/3378422/29517/en/mannkind-data-at-hfsa-2026-highlights-new-evidence-supporting-furoscix-readyflow-for-the-outpatient-management-of-edema-in-heart-failure-hf-and-chronic-kidney-disease-ckd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","VHT","BK4188","TCAF","HF","BK4218","LU1169590202.USD","BK4585","CGCV","BK4550","PK","ASM","BK4181","BK4139","PD","NOBL","LU1169589451.USD","BK4584","BK4588","KBWY","BK4023","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674866345","title":"Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674866345","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674866345?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:32","pubTimestamp":1791567135,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical (COLL) should benefit from continued strength in its attention-deficit/hyperactivity disorder drugs, limited near-term generic risk for Belbuca and stable pricing trends, whil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TEVA","BK4557","LU2324357040.USD","BK4596","BK4559","COLL","BK4585","BK4584","BK4588","BK4139","BK4007","ABVC","BK4566","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674866558","title":"Teva Pharmaceutical on Track for Highest Close Since February 2017","url":"https://stock-news.laohu8.com/highlight/detail?id=2674866558","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674866558?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:32","pubTimestamp":1791567120,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries Limited  is currently at $41.55, up $2.30 or 5.86%--Would be highest close since Feb. 15, 2017, when it closed at $51.06--On pace for largest percent increase since Aug. 12, 2026, when it rose 30.28%--Currently up five of the past six days--Currently up three consecutive days; up 6.18% over this period--Best three-day stretch since the three days ending Aug. 14, 2026, when it rose 30.28%--Up 5.11% this week; best weekly performance since the week ending Sept. 18, 2026, when it rose 5.35%--Up 4.92% month-to-date--Up 45.23% year-to-date; on pace for best year since 2024, when it rose 149.59%--Down 39.99% from its all-time closing high of $69.24 on Sept. 1, 2015--Up 107.65% from 52 weeks ago , when it closed at $20.01--Would be a new 52-week closing high--Up 124.59% from its 52-week closing low of $18.50 on Nov. 12, 2025--Traded as high as $42.02; highest intraday level since Feb. 15, 2017, when it hit $51.06--Up 7.06% at today's intraday high; largest intra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4584","LU1983299246.USD","BK4596","LU2324357040.USD","TEVA","BK4588","BK4559","BK4585","BK4566","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674286523","title":"Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674286523","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674286523?lang=en_us&edition=fundamental","pubTime":"2026-10-10 00:52","pubTimestamp":1791564767,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  Weltruza approval removes the label risk that defined the long-acting olanzapine debate, leaving launch execution as the key question, Oppenheimer said in a note Friday.With no REMS, no post-injection observation requirement and no boxed warning for post-injection delirium sedation syndrome, Weltruza is the first practical olanzapine LAI, the firm said.Oppenheimer expects a quiet first half of 2027 focused on sampling, hospital formularies and state-by-state Medicaid additions, with meaningful revenue in the second half. It said the launch should be judged on samples, formulary wins and prescriptions, not early sales.The $3,950 monthly list price, 47% above Oppenheimer's initial assumption, signals Teva's confidence in the profile, the firm said. It assumes a 40% gross-to-net discount and flagged rebate depth as the key variable through 2027.Oppenheimer raised its price target to $52 from $50 and reiterated its outperform rating.Price: 41.64, Change: +2","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4596","LU2324357040.USD","LU1983299246.USD","BK4584","BK4585","BK4557","BK4007","BK4566","BK4559","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674859554","title":"Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2674859554","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674859554?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:36","pubTimestamp":1791545799,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said Friday that the US Food and Drug Administration has approved WELTRUZA for extended-release injectable suspension of olanzapine for subcutaneous use as a treatment of schizophrenia in adults.The company said WELTRUZA will be available in the US in the coming weeks in once-monthly subcutaneous injectable doses of 318 mg, 425 mg and 531 mg.The injections will not require loading doses, oral supplementation, or post-injection monitoring, the company said.Teva said approval was based on results from its phase-3 Solaris trial, which showed a significant reduction in illness severity and improvement in personal and social functioning.The company said the treatment's safety profile was consistent with oral olanzapine, while reported adverse events included weight gain, sleepiness, headache, constipation and injection-site reactions.Shares of the company were up 3.4% in Friday's premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4559","LABU","TEVA","LU1983299246.USD","BK4588","BK4585","BK4007","BK4584","BK4557","LU2324357040.USD","BK4596","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674785642","title":"Teva announces FDA approval for Weltruza","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785642","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785642?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543924,"startTime":"0","endTime":"0","summary":"Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","SYNB","NVIB","LFSC","LABU","IDNA","BK4566","LU2324357040.USD","MRNX","MRNY","MEDI","BK4007","BBP","IEIH","GNMX","IYH","TBXU","BK4585","RSPH","XLVX","LU1983299246.USD","BK4559","BK4588","PINK","BK4584","PSCH","BK4557","BK4596","FRTY","IBB","BMED","TEVA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673008528","title":"Dare Bioscience to present Sildenafil Cream data at SMSNA meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673008528","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673008528?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:25","pubTimestamp":1791465909,"startTime":"0","endTime":"0","summary":"Dare Bioscience (DARE) announced that clinical data from a Phase 1 study that evaluated the company’s proprietary Sildenafil Cream, 3.6% investigat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dare-bioscience-to-present-sildenafil-cream-data-at-smsna-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dare-bioscience-to-present-sildenafil-cream-data-at-smsna-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673070904","title":"Daré Bioscience Reports Phase 1 Data Showing 187-Fold Lower Peak Plasma Sildenafil with 3.6% Topical Cream vs Oral Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2673070904","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673070904?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:15","pubTimestamp":1791465319,"startTime":"0","endTime":"0","summary":"Daré Bioscience reports Phase 1 data showing 187-fold lower peak plasma sildenafil with 3.6% topical cream vs oral doseDaré Bioscience disclosed Phase 1 results for a topical sildenafil cream, with da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL6LNWVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","SG9999014005.SGD","BK4584","IE00BQXX3C00.GBP","BCDF","SG9999014039.USD","DARE","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU2095319765.USD","NDAQ","IE00BQXX3F31.USD","BK4007","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4585","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673070842","title":"Femasys to Exhibit at ASRM Scientific Congress & Expo","url":"https://stock-news.laohu8.com/highlight/detail?id=2673070842","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673070842?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:03","pubTimestamp":1791464581,"startTime":"0","endTime":"0","summary":"Femasys to exhibit at ASRM Scientific Congress & ExpoFemasys will exhibit at the ASRM 2026 Scientific Congress & Expo on Oct. 24-28 in Baltimore.Showcase to feature FemaSeed intratubal insemination, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLKP7Bp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","SG9999014005.SGD","BK4584","IE00BQXX3C00.GBP","BCDF","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU2095319765.USD","NDAQ","IE00BQXX3F31.USD","BK4082","BK4112","FEMY","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4539","IE00BKPKM429.USD","BK4585","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}